Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer
|
|
- Thomasine Horn
- 8 years ago
- Views:
Transcription
1 Emerging Role of Aromatase Inhibitors in the Treatment of Breast Cancer Review Article [1] March 02, 1998 By Harold A. Harvey, MD [2] The new generation of potent steroidal and nonsteroidal inhibitors of the enzyme aromatase act by decreasing estrogen production throughout the body in postmenopausal women. The most potent of these agents may also inhibit estrogen synthesis within metastatic breast cancer tissue. The hormone dependence of some forms of human breast cancer was first suggested by the pioneering work of Beatson in 1896.[1] Subsequent refinement of this concept and description of the role of the estrogen receptor by Jensen et al led to an appreciation of the fundamental action of estrogen in mediating the differentiation and growth of primary and metastatic mammary carcinoma.[2] Hormone-dependent breast cancer is characterized by the presence of steroid hormone (estrogen and progesterone) receptors. Estrogen receptor (ER)-positive tumors tend to be more indolent in their clinical behavior and are more common in older women. Most important, when metastatic, this tumor subtype can be effectively managed by the sequential use of various hormonal manipulations. Major endocrine ablative therapies, such as hypophysectomy and adrenalectomy, have been replaced by more elegant pharmacologic approaches. These approaches derive from our better understanding of the mechanisms of hormonal action, receptor physiology, and the biology of the autocrine growth control of breast cancer by in situ estrogen synthesis, as well as paracrine control, mediated by a variety of growth factors and their receptors. Current Hormonal Approaches Blockade of ER action by antiestrogen therapy with tamoxifen (Nolvadex) or other triphenylethylene derivatives, such as toremifene (Fareston) or droloxifene, is currently the best approach to the endocrine treatment of breast cancer in both the adjuvant and palliative settings.[3] In patients whose disease progresses following antiestrogen therapy and who remain candidates for further endocrine therapy, however, new treatment strategies must be adopted. Since there is little evidence for non-cross-resistance among the currently available antiestrogens, there is no clinical advantage to be gained by switching therapy from one of these compounds to another. Traditionally, progestins have been used as the second-line hormonal therapy in this clinical situation. The mechanism of action of progestins in this setting is complex and poorly understood. In contrast, the blockade of estrogen synthesis by agents that inhibit aromatase activity has now been well studied, and several new agents are available for clinical use.[4] This paper will demonstrate that the new class of aromatase inhibitors should now be considered as an alternative to progestins for second-line hormonal therapy. Importance of Aromatase In postmenopausal women, the majority of circulating biologically active estrogens, including estrone and estradiol, are formed by the enzymatic conversion of androstenedione and testosterone secreted by the adrenal glands. This process of aromatization occurs at peripheral sites, such as adipose tissue, liver, and muscle. Another important target for the inhibition of aromatase activity is breast cancer tissue itself, since some tumors have been shown to be capable of the local synthesis of estrogens.[5] Development of Aromatase Inhibitors Aminoglutethimide was the first aromatase inhibitor to be widely tested in postmenopausal women with metastatic hormone-dependent breast cancer. Worldwide experience demonstrated that the regimen of aminoglutethimide and hydrocortisone was, indeed, very effective in producing clinical responses in women with ER-positive, advanced breast cancer.[6]this regimen was associated with Page 1 of 5
2 troublesome clinical toxicity, however. It also was not specific for aromatase inhibition, since levels of other cytochrome P450 synthesis-dependent hormones, including cortisol, aldosterone, and thyroid hormone, could be affected. More recently, several nonsteroidal imidazole and triazole derivatives have been synthesized as competitive inhibitors of aromatase. These new compounds are potent and highly selective for aromatase inhibition. The newer aromatase inhibitors show promising clinical activity when used as second-line therapy for metastatic disease in postmenopausal women. Furthermore, these new drugs produce minimal side effects. Comparative Trials The specificity and potency of the new compounds were first demonstrated in a number of phase I and II trials that included careful measurement of steroid hormone levels in normal volunteers and postmenopausal women with breast cancer before and after treatment with both competitive and mechanism-based suicide-type steroidal inhibitors.[7-9] Recently Approved Aromatase Inhibitors Several large, randomized, phase III clinical trials of the new aromatase inhibitors have been reported recently, and the results of some of these pivotal trials were the basis for FDA approval of two of these agents. Most of these trials enrolled postmenopausal patients in whom disease had progressed during tamoxifen therapy but who were still deemed eligible for further hormonal treatment and had either measurable or evaluable metastatic disease. In many of the trials, the standard treatment was megestrol acetate (40 mg PO qid or 160 mg qd). The results of two large, international, multicenter, prospective randomized trials comparing anastrozole (Arimidex), 1 or 10 mg, to megestrol acetate have been combined and show similar response rates of approximately 35% for both doses of anastrozole and megestrol acetate. However, in this pivotal trial, women receiving anastrozole experienced significantly less weight gain and overall fewer thromboembolic events, compared to patients treated with megestrol.[10] On the basis of these results, anastrozole, in a dose of 1 mg once daily, became the first aromatase inhibitor to be approved in the United States for the treatment of postmenopausal women with metastatic breast cancer. A recent follow-up of this study now shows an improved time to tumor progression and survival in women treated with anastrozole compared to megestrol acetate.[11] A trial of similar design comparing letrozole (Femara) to megestrol acetate reported response rates of 23.6% vs 16.4% and a trend toward a longer time to tumor progression favoring the aromatase inhibitor. In this study, letrozole was somewhat better tolerated than megestrol.[12] In another trial, letrozole was compared to aminoglutethimide in a similar group of patients and was deemed to be more effective and less toxic.[13] On the basis of these recent trials, letrozole, in a dose of 2.5 mg once daily, was the second aromatase inhibitor to gain FDA approval and is now being marketed with an indication similar to that for anastrozole. Some in vitro laboratory studies and hormonal measurements in patients suggest that letrozole may produce a higher degree of aromatase inhibition than does anastrozole. The clinical significance of these findings is unknown and speculative.[14] Other Aromatase Inhibitors Studies comparing vorozole to megestrol and aminoglutethimide have also been reported.[15] These preliminary reports seem to show a therapeutic advantage for the aromatase inhibitor, but vorozole has not yet been approved for clinical use. In another trial, fadrozole was compared to megestrol acetate and produced a similar response rate and median time to progression.[16] Fadrozole has been compared to tamoxifen as first-line endocrine therapy in postmenopausal women with metastatic breast cancer, and the two agents produced similar clinical results.[17] Since both anastrozole and letrozole are more potent and selective than fadrozole, it is unlikely that this agent will be developed further. Exemestane is a nonsteroidal, specific, irreversible inhibitor of aromatase that is currently undergoing active clinical trials. Selection of Patients Extensive clinical experience in breast cancer management has shown that the selection of patients who are ideally suited for hormonal therapies can be reliably based on a consideration of a number of clinical parameters. These include the presence of both estrogen and progesterone receptors in the tumor, a long disease-free interval, patient age, absence of rapidly progressing or visceral dominant disease, and prior response to other hormonal therapies. Page 2 of 5
3 The same criteria have now been shown to apply to the selection of patients for treatment with the new aromatase inhibitors. It has been speculated that the ability to assess aromatase content in individual tumors (eg, by immunohistochemistry) may help identify patients who are most likely to respond specifically to aromatase inhibitors. The fact that the expression of aromatase activity in some metastatic lesions does not always correlate with the presence of ERs also suggests the possibility of activity of aromatase inhibitors in patients who do not respond to other hormones.[18] None of these hypotheses has been rigorously tested, however. To date, there is no clinical evidence to support the use of aromatase inhibitors, even the new potent ones, in premenopausal patients. In the future, measurement of other tumor parameters, such as expression of Her-2/neu and p53, may prove useful in predicting the state of hormonal resistance and, therefore, the lack of response to conventional endocrine therapies, including aromatase inhibitors.[19] Sequence of Therapy Given the increasing number of agents available for hormone-dependent breast cancer, the clinician must decide on an optimal sequence for their use. Sequential therapy of these palliative modalities is preferable, since no clinical data support the use of combined hormonal therapies outside of an investigational protocol. In the premenopausal patient, ovarian ablation, luteinizing hormone-releasing hormone (LHRH) analogs, and tamoxifen produce similar clinical results in metastatic disease. In the postmenopausal patient with hormone-dependent breast cancer, antiestrogens remain the mainstay of endocrine therapy. Tamoxifen and related compounds, such as toremifene and droloxifene, have similar activities. Choice among these agents must be based on clinical experience and the degree of concern for side effects in individual patients. There is little evidence to support crossover treatment, for example, switching from tamoxifen to toremifene or vice versa, in the face of disease progression. In a patient whose disease has progressed > 1 year after completing adjuvant tamoxifen therapy, on the other hand, resumption of therapy with an antiestrogen is probably worthwhile. In patients whose disease is refractory to antiestrogen therapy but who are still likely to have hormone-responsive metastases, treatment with an aromatase inhibitor should be initiated, in preference to the traditional approach of using megestrol acetate. No data support switching such patients from anastrozole to letrozole or vice versa. Progestin therapy probably should now be reserved for third-line therapy in patients whose disease progresses after response to aromatase inhibitors. Conclusions The aromatase inhibitors are an important class of agents with a well-understood mechanism of action in the treatment of breast cancer in postmenopausal women; namely, inhibition of estrogen biosynthesis. The newly approved compounds anastrozole and letrozole are potent and highly selective anastrozole inhibitors, are administered orally once daily, do not require coadministration of glucocorticoids, and are free of estrogenic activity. Randomized clinical trials show that both anastrozole and letrozole are well tolerated and do not cause undesired weight gain or significant thromboembolic side effects. Both agents are active against metastatic disease in patients who no longer respond to tamoxifen. Aromatase inhibitors are recommended as second-line palliative hormonal therapy in women with hormone-dependent breast cancer. These agents have not been tested in premenopausal patients. Clinical trials are currently comparing aromatase inhibitors to antiestrogen as first-line endocrine therapy. Studies of their possible roles as adjuvant therapy or chemoprevention for breast cancer are also being planned. The introduction of these new drugs affords patients and clinicians expanded options for securing good quality of life and palliation of advanced hormone-dependent breast cancer. References: 1. Beatson G: On the treatment of inoperable cases of carcinoma of the mammal. Lancet 2: , Evans RM: The steroid and thyroid hormone receptor family. Science 240: , Page 3 of 5
4 3. Forbes JF: The control of breast cancer: The role of tamoxifen. Semin Oncol 24(suppl 1):5-19, Harvey HA: Aromatase inhibitors in clinical practice: Current status and a look to the future. Semin Oncol 23(4;suppl 9):33-38, Santner SJ, Pauley RJ, Tait L, et al: Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 82(1): , Santen RJ, Samojlik E, Lipton A, et al: Kinetic hormonal and clinical studies with aminoglutethimide in breast cancer. Cancer 39: , Lipton A, Demers LM, Harvey H, et al: Letrozole (CGS 20267): Phase I study of a new potent oral aromatase inhibitor in breast cancer. Cancer 75(8): , Demers LM: Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 30(1):95-102, Masamura S, Aldercreutz H, Harvey HA, et al: Aromatase inhibitor development for treatment of breast cancer. Breast Cancer Res Treat 33(1):19-26, Buzdar A, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14(7): , Buzdar A, Jonat W, Howell A, et al: Significant improved survival with Arimidex (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: Updated results of two randomized trials (abstract). Proc Am Soc Clin Oncol 16:156a, Dombernowski P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: , Marty M, Gershanovich M, Campos B, et al: Letrozole, a new, potent, selective aromatase inhibitor superior to aminoglutethimide in postmenopausal women with advanced breast cancer previously treated with antiestrogens (abstract). Proc Am Soc Clin Oncol 16:156a, Demers LM, Lipton A, Harvey HA, et al: The efficacy of CGS (letrozole) in suppressing estrogen biosynthesis in patients with advanced stage breast cancer. J Steroid Biochem Mol Biol 44(4-6): , Goss P, Wine E, Tannock I, et al: Vorozole versus Megace in postmenopausal patients with metastatic breast carcinoma who had relapsed following tamoxifen (abstract). Proc Am Soc Clin Oncol 16:156a, Buzdar AU, Smith R, Vogel C, et al: Fadrozole HCl (CGS 16949A) vs megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trials. Cancer 77(12): , Thurliman S, Beretta K, Bacchi M, et al: First line fadrozole hydrochloride vs tamoxifen in advanced breast cancer: Prospective randomized study (abstract). Proc Am Soc Clin Oncol 14:98a, Lipton A, Santner SJ, Santen RJ, et al: Aromatase activity in primary and metastatic human breast cancer. Cancer 59: , Leitzel K, Teramoto Y, Konrad K, et al: Elevated serum c-erb-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol 13(5): , Page 4 of 5
5 Source URL: Links: [1] [2] Page 5 of 5
Treatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationClinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer
Clinical Trial Designs for Firstline Hormonal Treatment of Metastatic Breast Cancer Susan Honig, M.D. Patricia Cortazar, M.D. Rajeshwari Sridhara, Ph.D. Acknowledgements John Johnson Alison Martin Grant
More informationFulvestrant in Heavily Pretreated Metastatic Breast Cancer: Is It Still Effective as a Very Advanced Line of Treatment?
Fulvestrant in Heavily Pretreated Metastatic Breast Cancer: Is It Still Effective as a Very Advanced Line of Treatment? Tamar Safra MD *, Julia Greenberg MD *, Ilan G. Ron MD, Rami Ben Yosef MD, Moshe
More informationFlorida Breast Health Specialists Hormone Therapy Information and Questions to Ask Your Doctor
What is Hormone Therapy? Hormonal therapy medicines are whole-body (systemic) treatment for hormone-receptorpositive breast cancers. Hormone receptors are like ears on breast cells that listen to signals
More informationHormones & Hormone Antagonists Chapter 40 - Katzung
Hormones & Hormone Antagonists hapter 40 - Katzung Least toxic of anticancer drugs Highly selective Breast, endometrial, prostate cancers 5 ategories Androgens Progestins Antiandrogens Gonadotropin-releasing
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationSpecial pediatric considerations are noted when applicable, otherwise adult provisions apply.
DRUG NAME: Letrozole SYNONYM(S): Letzazole, CGS 20267 COMMON TRADE NAME(S): FEMARA (notice of compliance, 1 May 1997; patent expires 2 April 2010) CLASSIFICATION: Aromatase inhibitor Special pediatric
More informationAromatase Inhibitors. in the Treatment of. Breast Cancer
3 rd Generation Non-steroidal Aromatase Inhibitors in the Treatment of Breast Cancer This paper is being provided to the Class of 2007 as an example of a Master s Project paper, and should be used solely
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationCombination Endocrine Therapy in the Management of Breast Cancer
Combination Endocrine Therapy in the Management of Breast Cancer LAURA BOEHNKE MICHAUD, KELLIE L. JONES, AMAN U. BUZDAR The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words.
More informationControversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies
Annals of Oncology 15 (Supplement 4): iv23 iv29, 2004 doi:10.1093/annonc/mdh901 Controversies in the adjuvant treatment of breast cancer: new adjuvant endocrine treatment strategies V. D Hondt & M. Piccart
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationDECISION AND SUMMARY OF RATIONALE
DECISION AND SUMMARY OF RATIONALE Indication under consideration Clinical evidence Everolimus in combination with exemestane hormone therapy for oestrogen receptor positive locally advanced or metastatic
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationNational Pharmaceutical Pricing Authority 3 rd Floor, YMCA Cultural Centre 1 Jai Singh Road New Delhi 110001 File No. 23(01)2014/Div.
Dated 21 st November 2014 NPPA Invites Comments of Pharmaceutical Industry & Trade, Consumer Organisations, Public Health Experts and other Stakeholders on the Recommendations of Tata Memorial Centre under
More informationRecommendation Strength Strong, supported by the evidence and expert consensus. Recommendation Benefit/Harm Evidence Quality
CHEMO- AND TARGETED THERAPY FOR WOMEN WITH HER2 NEGATIVE (OR UNKNOWN) ADVANCED BREAST Benefit/Harm Evidence Quality 1: Endocrine therapy, rather than chemotherapy, should be offered as the standard firstline
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationJ Clin Oncol 23:619-629. 2005 by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 3 JANUARY 20 2005 JOURNAL OF CLINICAL ONCOLOGY A S C O S P E C I A L A R T I C L E American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant
More informationCancer patients waiting for potentially live-saving treatments in UK
Cancer patients waiting for potentially live-saving treatments in UK 29 May 2005 UK patients are waiting too long for new treatments, according to a 'Dossier of Delay' compiled by information charity CancerBACUP.
More informationMetastatic Breast Cancer: The Art and Science of Systemic Therapy. Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba
Metastatic Breast Cancer: The Art and Science of Systemic Therapy Vallerie Gordon MD, FRCPC Medical Oncologist CancerCare Manitoba Presenter Disclosure Faculty: Dr. Vallerie Gordon Relationships with commercial
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationBackground. t 1/2 of 3.7 4.7 days allows once-daily dosing (1.5 mg) with consistent serum concentration 2,3 No interaction with CYP3A4 inhibitors 4
Abstract No. 4501 Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a Phase III randomized, open-label, multicenter trial R. Motzer, D.
More informationGemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer Review Article [1] December 01, 2003 By George W. Sledge, Jr, MD [2] Gemcitabine (Gemzar) and paclitaxel show good activity as single
More informationOptimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient
Optimizing chemotherapy-free survival for the ER/HER2 positive metastatic breast cancer patient Stefan Glück, Carlos L. Arteaga, and Kent Osborne, University of Miami s Sylvester Comprehensive Cancer Center,
More informationF Montemurro 1, G Rondón 2, NT Ueno 2, M Munsell 3, JL Gajewski 2 and RE Champlin 2. Summary:
(2002) 29, 861 866 2002 Nature Publishing Group All rights reserved 0268 3369/02 $25.00 www.nature.com/bmt Breast cancer Factors affecting progression-free survival in hormone-dependent metastatic breast
More information3. Chemotherapy. "Practice Guidelines for Breast Cancer" Research. Questions. NCCN/JCCNB Seminar in Japan January 13-14, 2007 January 26-27, 2008
NCCN/JCCNB Seminar in January 13-14, 2007 January 26-27, 2008 "Practice Guidelines for Breast Cancer" A Comparison between and (: as of 2007, : according to "Practice Guideline for Breast Cancer"(2005)
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationKanıt: Klinik çalışmalarda ZYTIGA
mkdpk de Sonunda Gerçek İlerleme! Kanıt: Klinik çalışmalarda ZYTIGA Dr. Sevil Bavbek 5. Türk Tıbbi Onkoloji Kongresi Mart 214, Antalya Endocrine therapies Adrenals Testis Abiraterone Orteronel Androgen
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationInteligentaj decidoj... Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms. Intelligent Questions?
Intelligente Entscheide bei der adjuvanten Therapie des Mammakarzinoms Stefan Aebi Universitätsspital Bern, Inselspital Klinik für Medizinische Onkologie und Brust /Tumorzentrum der Frauenklinik Inteligentaj
More informationGuidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products
Guidance for Industry FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationTestosterone for women, who when and how much?
Medicine, Nursing and Health Sciences Testosterone for women, who when and how much? Susan R Davis MBBS FRACP PhD Women s Health Research Program School of Public Health Monash University Melbourne Medicine,
More informationAdvances In Chemotherapy For Hormone Refractory Prostate Cancer. TAX 327 study results & SWOG 99-16 study results presented at ASCO 2004
Ronald de Wit Rotterdam Cancer Institute The Netherlands Advances In Chemotherapy For Hormone Refractory Prostate Cancer TAX 327 study results & SWOG 99-16 study results presented at Slide 1 Prostate Cancer
More informationEndocrine Responses to Resistance Exercise
chapter 3 Endocrine Responses to Resistance Exercise Chapter Objectives Understand basic concepts of endocrinology. Explain the physiological roles of anabolic hormones. Describe hormonal responses to
More informationMale Breast Cancer Edward Yu, MD PhD, FRCPC. Department of Oncology, Western University, London, Ontario, Canada
1 Male Breast Cancer Edward Yu, MD PhD, FRCPC. Department of Oncology, Western University, London, Ontario, Canada Epidemiology Male breast cancer (MBC) is a rare disease worldwide. MBC accounts for approximately
More informationBREAST CANCER WHAT HAPPENS AFTER SURGERY?
BREAST CANCER WHAT HAPPENS AFTER SURGERY? Contents: Planning further treatment Medical management of breast cancer Support and follow up Questions to ask your surgeon or oncologist Planning further treatment
More informationQuality of life in MAP.3: A randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer
The following protocol information is provided solely to describe how the authors conducted the research underlying the published report associated with the following article: Quality of life in MAP.3:
More informationONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico
ONCOLOGIA: esperienze cliniche a confronto. Il carcinoma mammario metastatico Sequenza ottimale del trattamento Maria Teresa Scognamiglio U.O.C. Clinica Oncologica Chieti-Ortona Chieti 12 novembre 213
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationGuidance for Industry
Guidance for Industry Cancer Drug and Biological Products Clinical Data in Marketing Applications U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and
More informationFACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN
FACT SHEET TESTETROL, A NOVEL ORALLY BIOACTIVE ANDROGEN General Pantarhei Bioscience B.V. is an emerging specialty pharmaceutical company with a creative approach towards drug development. The Company
More informationClinical Management Protocol Chemotherapy Breast Cancer. Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: BREAST CANCER Patient information given at each stage following agreed information pathway
More informationAbstract Introduction. Aim of the study. Conclusion. Patients and methods. Keywords. Results. R. Abo El Hassan 1, M. Moneer 2
Original Study Outcome of HER2 positive luminal operable breast cancer in comparison with outcome of other operable luminal breast cancer patients: Long follow-up of single center randomized study R. Abo
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationPI3K signaling pathway a new target for breast cancer treatment
PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationNational Horizon Scanning Centre. Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer. December 2007
Vandetanib (Zactima) for advanced or metastatic non-small cell lung cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search.
More informationGuidelines on endocrine therapy of breast cancer EUSOMA
European Journal of Cancer 38 (2002) 615 634 Position Paper Guidelines on endocrine therapy of breast cancer EUSOMA R.W. Blamey a,b, * a Nottingham City Hospital, NG5 1PB, UK b EUSOMA, Corso Italia 16,
More informationOne of the most mature trials that examined PROCEEDINGS. Hormone Therapy in Postmenopausal Women With Breast Cancer * William J.
Hormone Therapy in Postmenopausal Women With Breast Cancer * William J. Gradishar, MD ABSTRACT *Based on a presentation given by Dr Gradishar at a roundtable symposium held in Baltimore on June 28, 25.
More informationAging Well - Part V. Hormone Modulation -- Growth Hormone and Testosterone
Aging Well - Part V Hormone Modulation -- Growth Hormone and Testosterone By: James L. Holly, MD (The Your Life Your Health article published in the December 4th Examiner was a first draft. It was sent
More informationEndocrine therapy of breast cancer
DOI: 10.1093/annonc/mdf640 Endocrine therapy of breast cancer A. Goldhirsch 1,2, M. Colleoni 3 & R. D. Gelber 4 1 Department of Medicine, European Institute of Oncology, Milan, Italy; 2 Oncology Institute
More informationThe Clinical Trials Process an educated patient s guide
The Clinical Trials Process an educated patient s guide Gwen L. Nichols, MD Site Head, Oncology Roche TCRC, Translational and Clinical Research Center New York DISCLAIMER I am an employee of Hoffmann-
More informationGynäkologische Onkologie-Klinische Studien
Gynäkologische Onkologie-Klinische Studien Breast cancer A randomized, phase 2 trial of AEZS-108 in chemotherapy refractory triple negative (ER/PR/HER2-negative) LHRH-R positive metastatic breast cancer
More informationOlof H. Pearson, Andrea Manni, and Baha'uddin
(CANCER RESEARCH (SUPPL.) 42. 3424s-3429s. August 1982] 0008-5472/82/0042-OOOOS02.00 Antiestrogen Treatment of Breast Cancer: An Overview1 Olof H. Pearson, Andrea Manni, and Baha'uddin M. Arafah Department
More informationIBRANCE is not approved for any indication in any market outside the U.S.
IBRANCE (palbociclib) Fact Sheet IBRANCE (palbociclib) is an oral inhibitor of cyclin-dependent kinases (CDKs) 4 and 6. IBRANCE is indicated in combination with letrozole for the treatment of postmenopausal
More informationInformation and Insight into Breast Cancer in China. White Paper. by Neesha Suvarna, PhD Consultant, Kantar Health November 2011
White Paper Catalysts driving successful decisions in life sciences. Information and Insight into Breast Cancer in China by Neesha Suvarna, PhD Consultant, Kantar Health November 2011 www.kantarhealth.com
More informationAdjuvant Therapy for Breast Cancer: Questions and Answers
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Adjuvant Therapy for Breast
More informationBreast Cancer Treatment
Breast Cancer Treatment Most women with breast cancer will have surgery. The two common types of surgery are breast-conserving surgery and mastectomy. Breast Conserving Surgery A lumpectomy removes only
More informationPSA Testing 101. Stanley H. Weiss, MD. Professor, UMDNJ-New Jersey Medical School. Director & PI, Essex County Cancer Coalition. weiss@umdnj.
PSA Testing 101 Stanley H. Weiss, MD Professor, UMDNJ-New Jersey Medical School Director & PI, Essex County Cancer Coalition weiss@umdnj.edu September 23, 2010 Screening: 3 tests for PCa A good screening
More informationFoundational Issues Related to Immunotherapy and Melanoma
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationBreastCancerTrials.org History Form: Metastatic Breast Cancer ABOUT ME
BreastCancerTrials.org History Form: Metastatic Breast Cancer This form is for patients with metastatic breast cancer who were: Were recently diagnosed with metastatic breast cancer (cancer that has spread
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationEvaluation of Treatment Pathways in Oncology: An Example in mcrpc
Evaluation of Treatment Pathways in Oncology: An Example in mcrpc Sonja Sorensen, MPH United BioSource Corporation Bethesda, MD 1 Objectives Illustrate selection of modeling approach for evaluating pathways
More informationClinical Trial Design. Sponsored by Center for Cancer Research National Cancer Institute
Clinical Trial Design Sponsored by Center for Cancer Research National Cancer Institute Overview Clinical research is research conducted on human beings (or on material of human origin such as tissues,
More informationFrom Menses to Menopause: How Hormones Can Affect Blood Glucose Levels. Christine Day, RN, MS, CNS-BC Lake Superior College
From Menses to Menopause: How Hormones Can Affect Blood Glucose Levels Christine Day, RN, MS, CNS-BC Lake Superior College Overview Will review hormonal changes over the female lifespan Discuss the effects
More informationJanuary 2013 LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Summary. Contents
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/paclitaxel for cancer Paclitaxel albumin (Abraxane ) as a substitute for docetaxel/ paclitaxel for
More informationKidney Cancer OVERVIEW
Kidney Cancer OVERVIEW Kidney cancer is the third most common genitourinary cancer in adults. There are approximately 54,000 new cancer cases each year in the United States, and the incidence of kidney
More informationMETASTATIC BREAST CANCER
METASTATIC BREAST CANCER Executive Summary Metastatic breast cancer is defined as disease beyond the breast and regional lymph nodes. Although metastatic breast cancer is generally incurable, patients
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationHORMONE THERAPY AND CHEMOTHERAPY
A SHARED DECISION-MAKING PROGRAM Early breast cancer HORMONE THERAPY AND CHEMOTHERAPY Are they right for you? BCA001B V06 Early breast cancer HORMONE THERAPY AND CHEMOTHERAPY Are they right for you? This
More informationAge Management Panel Male Fasting Panel
801 SW 16th St Suite 126 Renton WA 98057 Phone: 425.271.8689 Fax: 425.271.8689 CLIA # 50D0630590 Age Management Panel Male Fasting Panel Doctor ID 1001 Age 55 Date Collected 01/01/07 Patient Name DOE,
More informationUs TOO University Presents: Understanding Diagnostic Testing
Us TOO University Presents: Understanding Diagnostic Testing for Prostate Cancer Patients Today s speaker is Manish Bhandari, MD Program moderator is Pam Barrett, Us TOO International Made possible by
More informationLow dose capecitabine is effective and relatively nontoxic in breast cancer treatment.
1 Low dose capecitabine is effective and relatively nontoxic in breast cancer treatment. John T. Carpenter, M.D. University of Alabama at Birmingham NP 2508 1720 Second Avenue South Birmingham, AL 35294-3300
More informationBNC105 PHASE II RENAL CANCER TRIAL RESULTS
ABN 53 075 582 740 ASX ANNOUNCEMENT 19 March 2014 BNC105 PHASE II RENAL CANCER TRIAL RESULTS Results show BNC105 utility in patients with advanced disease Identified biomarkers which correlate with patient
More informationTECHNICAL INSIGHTS TECHNOLOGY ALERT
TECHNICAL INSIGHTS TECHNOLOGY ALERT UNLOCKING BREAST CANCER TUMORS' DRUG RESISTANCE A troubling phenomenon in breast cancer treatment is that some patients tumors become resistant to treatments over time.
More informationMedicines to Reduce Breast Cancer Risk
Medicines to Reduce Breast Cancer Risk Should I take a drug to help reduce my breast cancer risk? If you are a woman who has a higher than average risk of breast cancer, you should know that drugs like
More informationNavigating GIST. The Life Raft Group June 12, 2008
Navigating GIST Clinical Trials The Life Raft Group June 12, 2008 Some observations: Annually, only 3% of adult patients participate in cancer clinical trials. Lara et. al; Evaluation of factors affecting
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationMesothelioma. Information for Patients and Families. identifying and evaluating experimental
Mesothelioma CLINICAL TRIALS Information for Patients and Families identifying and evaluating experimental treatments table of contents Pg. 2... Phases of a Clinical Trial Pg. 3... Mesothelioma and Clinical
More informationANASTROZOLE 1 MG FILM-COATED TABLETS. (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS
ANASTROZOLE 1 MG FILM-COATED TABLETS (Anastrozole) PL 40378/0123 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 11 Summary of Product Characteristics
More informationIs the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study
Turkish Journal of Cancer Volume 34, No.1, 2004 19 Is the third-line chemotherapy feasible for non-small cell lung cancer? A retrospective study MUSTAFA ÖZDO AN, MUSTAFA SAMUR, HAKAN BOZCUK, ERKAN ÇOBAN,
More informationPharmacogenetic Activities in SWOG Breast Cancer
Pharmacogenetic Activities in SWOG Breast Cancer Pharmacogenomics: Future Plans S8897 Adjuvant CMF vs. CAF/ no Treatment Ambrosone RO1: Other genes (TBCI approved, analyses ongoing) S0221 Adjuvant Dose
More informationGenomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationResearch Article Biological Characteristics and Medical Treatment of Breast Cancer in Young Women A Featured Population: Results from the NORA Study
SAGE-Hindawi Access to Research International Journal of Breast Cancer Volume 2, Article ID 534256, 6 pages doi:.46/2/534256 Research Article Biological Characteristics and Medical Treatment of Breast
More information2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older)
2016 Physician Quality Reporting System Data Collection Form: Oncology (for patients aged 18 and older) IMPTANT: Any measure with a 0% performance rate (100% for inverse measures) is not considered satisfactory
More informationEFFECTS OF CHEMOTHERAPY- INDUCED OVARIAN FAILURE ON BONE AND LIPID METABOLISM IN PREMENOPAUSAL BREAST CANCER PATIENTS
EFFECTS OF CHEMOTHERAPY- INDUCED OVARIAN FAILURE ON BONE AND LIPID METABOLISM IN PREMENOPAUSAL BREAST CANCER PATIENTS Impact of adjuvant clodronate and tamoxifen Leena Vehmanen Department of Oncology University
More informationBREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1
FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 Hello, my name is Rachel Jankowitz, I m an assistant professor of medicine in the Division of Hematology Oncology at the University of Pittsburgh
More informationOverview of Phase 1 Oncology Trials of Biologic Therapeutics
Overview of Phase 1 Oncology Trials of Biologic Therapeutics Susan Jerian, MD ONCORD, Inc. February 28, 2008 February 28, 2008 Phase 1 1 Assumptions and Ground Rules The goal is regulatory approval of
More informationTITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
More informationIn Practice Whole Body MR for Visualizing Metastatic Prostate Cancer
In Practice Whole Body MR for Visualizing Metastatic Prostate Cancer Prostate cancer is the second most common cancer in men worldwide, accounting for 15% of all new cancer cases. 1 Great strides have
More informationOffice of Population Health Genomics
Office of Population Health Genomics Policy: Protocol for the management of female BRCA mutation carriers in Western Australia Purpose: Best Practice guidelines for the management of female BRCA mutation
More informationReceptor conversion in distant breast cancer metastases. Breast cancer metastases: A spitting image of their primary?
Receptor conversion in distant breast cancer metastases Breast cancer metastases: A spitting image of their primary? Introduction Breast cancer is the leading cause of female cancer death worldwide (13,000
More informationPellet Implant FAQ Provided By: Rebecca Glaser, MD, FACS www.hormonebalance.org
Understanding BHRT Pellet Implants Pellet Implant FAQ Introduction Data supports* that hormone replacement therapy with pellet implants is the most effective and the most bioidentical method to deliver
More information